What does aTyr Pharma do?
aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
Is life stock a buy?
aTyr Pharma has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
What is ATYR1923?
ATYR1923 is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need.
What kind of stock is life?
Common Stock (LIFE)
What is life expectancy with sarcoidosis?
What Is the Life Expectancy for Sarcoidosis? There is no cure for sarcoidosis, and in many cases, no treatment is required and patients recover on their own. Most patients have a normal life expectancy. About 1 to 8 percent of cases are fatal, and it depends on the severity and location of the disease.
Who is aTyr Pharma and what do they do?
SAN DIEGO , July 29, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent
When is the release date for atyr1923?
Sign-up to receive news as it is released using the email and RSS tools below. Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021 . Company to host conference call and webcast today, August 10th , at 5:00 p.m. EDT / 2:00 p.m. PDT .
When is the reverse split for aTyr Pharma?
The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split.
https://www.youtube.com/c/ATYRWR